Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment by Dong Lee et al.
Lee et al. Radiation Oncology 2012, 7:85
http://www.ro-journal.com/content/7/1/85RESEARCH Open AccessLong-term outcome and toxicity of
hypofractionated stereotactic body radiotherapy
as a boost treatment for head and neck cancer:
the importance of boost volume assessment
Dong Soo Lee1, Yeon Sil Kim2*, Jae Seok Cheon2, Jin Ho Song2, Seok Hyun Son2, Ji Sun Jang2, Young Nam Kang2,
Jing Hyoung Kang3, So Lyoung Jung4, Ie Ryung Yoo5 and Hong Seok Jang2Abstract
Background: The aim of this study was to report the long-term clinical outcomes of patients who received
stereotactic body radiotherapy (SBRT) as a boost treatment for head and neck cancer.
Materials and methods: Between March 2004 and July 2007, 26 patients with locally advanced, medically
inoperable head and neck cancer or gross residual tumors in close proximity to critical structures following head
and neck surgery were treated with SBRT as a boost treatment. All patients were initially treated with standard
external beam radiotherapy (EBRT). SBRT boost was prescribed to the median 80% isodose line with a median dose
of 21 (range 10–25) Gy in 2–5 (median, 5) fractions.
Results: The median follow-up after SBRT was 56 (range 27.6− 80.2) months. The distribution of treatment sites in
26 patients was as follows: the nasopharynx, including the base of the skull in 10 (38.5%); nasal cavity or paranasal
sinus in 8 (30.8%); periorbit in 4 (15.4%); tongue in 3 (11.5%); and oropharyngeal wall in 1 (3.8%). The median EBRT
dose before SBRT was 50.4 Gy (range 39.6− 70.2). The major response rate was 100% with 21 (80.8%) complete
responses (CR). Severe (grade≥ 3) late toxicities developed in 9 (34.6%) patients, and SBRT boost volume was a
significant parameter predicting severe late complication.
Conclusions: The present study demonstrates that a modern SBRT boost is a highly efficient tool for local tumor
control. However, we observed a high frequency of serious late complications. More optimized dose fractionation
schedule and patient selection are required to achieve excellent local control without significant late morbidities in
head and neck boost treatment.
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Radiation therapy is an established loco-regional treat-
ment for locally advanced head and neck cancers [1,2].
Although excellent results have been achieved with
advances in management schemes [2-4], local recurrence
continues to be a therapeutic challenge and one of the
major causes of treatment failure, especially in locally
advanced squamous cell carcinomas of the head and
neck [5,6]. Moreover, in cases of nasal cavity, paranasal* Correspondence: yeonkim7@catholic.ac.kr
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reproduction in any medium, provided the orsinus (PNS) or nasopharyngeal carcinoma (NPC), which
are neighboring critical structures (e.g., brainstem and
optic apparatus), dose escalation with conventional ex-
ternal beam radiotherapy (EBRT) is limited by the radi-
ation tolerance of the adjacent normal tissues.
It has been generally accepted that a dose–response
relationship exists between the applied radiation dose
and local tumor control [7,8]. Furthermore, absolute
local control is one of the essential prognostic indicators
for maintaining excellent long term clinical results.
The CyberKnife (Accuray, Sunnyvale, CA) was origin-
ally developed for high-precision stereotactic radiother-
apy. The feasibility, safety, and success in terms of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 SBRT dose-fractionation schedules
Number of patients Fractions Dose (Gy) BED10 (Gy) BED3 (Gy)
8 5 25 37.5 66.7
6 3 21 35.7 70
5 5 20 28 46.7
1 3 24 43.2 88
1 4 24 38.4 72
1 5 22.5 32.6 56.3
1 3 18 28.8 54
1 4 18 26.1 45
1 2 16 28.8 58.7
1 3 10 13.2 20.8
BED, Biologically equivalent dose.
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a boost, re-irradiation or palliative modality have been
previously reported [9-12]. However, long-term safety
profiles and normal tissue dose-volume constraints for
modern hypofractionated stereotactic body radiotherapy
(SBRT) are still not documented.
Our interim preliminary data have shown that SBRT
boosting might improve local tumor control through
increased radiation dosing with acceptable acute toxicity.
The purpose of the current study is to report the long-
term clinical outcome and toxicity of using SBRT as a
boost treatment for locally advanced head and neck
cancer.
Materials and methods
Study design and patient population
Patients who were treated with radiosurgery boosting
using the CK between March 2004 and July 2007 with
one the following characteristics were enrolled as sub-
jects into this study (N= 26): patients with locally
advanced or medically inoperable head and neck cancers
or patients with residual tumors that were adjacent to
the critical structures after surgery in the head and neck
region. More detailed characteristics of included patients
were as follows: locally advanced NPC patients who
needed high dose of radiation for local tumor control,
PNS or nasal cavity cancer patients whose tumors
located in close proximity to the orbital structure,
patients with minor salivary gland cancer arising from
orbital structures in which high radiation delivery is not
practically possible with conventional three-dimensional
(3-D) conformal approach, and medically inoperable T2-
T3 category of oral tongue cancer patients who needed
an efficient dose escalation tool after EBRT of 45 Gy in-
stead of brachytherapy boost.
We obtained Institutional Review Board approval for
this retrospective study. All of the patients were initially
treated with standard therapies, including 3-D conformal
EBRT. SBRT boost was administered to the gross tumor
volume (GTV) area 2 weeks after the completion of the
initial EBRT treatment. The SBRT schedule typically
consisted of dose between 10 and 25 Gy in 3 to 5 frac-
tions, and we adjusted the SBRT dose and fractionation
schedule according to the initial tumor site and type,
modality of initial treatment, and previous EBRT dose.
CyberKnife treatment procedures
The CK treatment procedure has been fully described pre-
viously [9,10]. In almost all cases, we performed image fu-
sion of pre-treatment 1-mm slice magnetic resonance
imaging (MRI) images with computed tomography (CT)
images that had been taken in the same positions to define
target volumes and critical structures. Although we could
achieve tumor shrinkage after EBRT in NPC patients,involved skull base and parapharyngeal mucosa often had
residual lesions. Therefore, we included aforementioned
areas as a SBRT boost volume. In non-NPC patients, re-
sidual tumors neighboring critical organs after EBRT (with
or without previous debulking surgery) were defined as a
SBRT boost volume. The planning target volume (PTV)
was defined as a radiographic GTV with a 1- to 2-mm
margin 3-D expansion. The PTV was slightly modified by
the surrounding critical structures, such as the optic
chiasm, optic nerve, brainstem, lens, globe, and spinal
cord. Dose constraints to normal structures were deter-
mined based on the EBRT dose and tumor locations.
These constraints included the total doses (EBRT and
SBRT dose) to the globe of <45− 50 Gy, optic nerves/
chiasm of <54− 60 Gy, and brainstem of <54− 60 Gy, un-
less there were direct tumor invasion into these
structures.
During the time period of this treatment, there was no
firmly established dose constraints guideline for normal
organs in hypofractionated RT. We planned to deliver
smallest possible doses to these organs; and higher doses
to the limited volumes of these structures were select-
ively allowed to appropriately cover the target volumes.
A total of 3 to 5 fractions were delivered for 3 to 5 con-
secutive days without inter-fractional break times. SBRT
dose-fractionation schedules used in our study are sum-
marized in Table 1.
Follow-up and response assessment
The patients were followed up at one-, three-, and six-
month intervals after SBRT treatment during the first
year; at every three- to six-month intervals during the
second year; and at every six-month interval thereafter.
During the follow-up periods, physical examination and
nasopharyngoscopy, in addition to CT, MRI or 18 F-
fluorodeoxyglucose (FDG) positron emission tomog-
raphy CT (PET-CT) imaging studies, were routinely per-
formed at usually every three-month after the
Table 2 Patient, tumor, and treatment characteristics
(N=26)
Characteristics Disease group [No. (%)]





Male:Female 8 (80): 2 (20) 12 (75): 4 (25)
Sites treated with SBRT
Nasopharynx and base of skull 10 (100)
Nasal cavity and PNS 8 (50)
Periorbit 4 (25)
Tongue 3 (18.8)
Oropharyngeal wall 1 (6.2)
Pathology
Type I NPC 2 (20)
Type II NPC 8 (80)
Squamous cell carcinoma 7 (43.8)
Adenoid cystic carcinoma 5 (31.3)
Chondrosarcoma 2 (12.5)
Malignant melanoma 1 (6.2)
Poorly differentiated adenocarcinoma 1 (6.2)
Tumor T stage
T4 7 (70) 7 (43.8)
T3 2 (20) 4 (25)
T2 1 (10) 5 (31.2)
Tumor N stage
N2 3 (30) 1 (6.3)
N1 6 (60) 2 (12.5)
N0 1 (10) 13 (81.2)
Previous debulking surgery
Yes:No 0 (0):10 (100) 11(68.8): 5 (31.2)
Combined chemotherapy
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six-month interval thereafter. Biopsies were performed
when clinically indicated.
The disappearance of tumors as evidenced by
contrast-enhanced CT, MRI, nasopharyngoscopy, and fi-
brotic changes that were inconsistent with the presence
of tumors with no evidence of progression in serial im-
aging studies were regarded as a complete response
(CR). A partial response (PR) was determined in the
same manner as a CR, and the tumor had to be reduced
by >50% but not completely gone.
Acute and late toxicities were assessed using the Na-
tional Cancer Institute Common Toxicity Criteria (NCI
CTCAE), version 4.0, and the Radiation Therapy Oncol-
ogy Group (RTOG) late toxicity criteria, respectively.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware (version 12.0, SPSS Inc., Chicago, IL, USA). Fisher’s
exact test and the Mann–Whitney U test were used to
compare variable distributions. Loco-regional
recurrence-free rate (LRRFR) and overall survival (OS)
were estimated using Kaplan-Meier curves, and survival
differences were assessed using log-rank tests. The Cox
proportional hazards regression model was used to iden-
tify independent prognostic factors. All statistical ana-
lyses were calculated based on the two-sided test, and a
p-value< 0.05 was considered to be significant.
Results
Patient characteristics
The median follow-up after SBRT treatment was 56 (range
27.6− 80.2) months, and 13 (50%) patients had died by the
time of the analysis. A complete history, physical examin-
ation, CT, MRI, PET-CT and nasopharyngoscopy were
routinely performed before the initial treatments, and
none of the patients showed evidence of distant metastasis
(DM) at the time of the initial diagnoses. All patients had
an Eastern Cooperative Oncology Group (ECOG) scale
score <2 with acceptable bone marrow, liver and renal
functions. Stage was based on clinical staging system in
NPC patients and patients who did not undergo surgery,
and pathologic staging system in patients who underwent
initial debulking surgery. Patient, tumor, and treatment
characteristics are described in Table 2.
Tumor and treatment characteristics
The median EBRT dose before SBRT was 50.4 (range
39.6− 70.2) Gy. The median SBRT dose was 21 (range
10–25) Gy in 2–5 (median 5) fractions. The median
PTV coverage was 98.2% (range 93.8− 100%), and the
median target volume was 28.2 (range 6.9− 69.4) cc. The
previous EBRT and SBRT doses were converted to bio-
logically equivalent doses (BEDs) based on a linear-
Table 2 Patient, tumor, and treatment characteristics
(N=26) (Continued)
Range 18-25 10-25
SBRT fractional dose (Gy)
Median 6.5 5
Range 5-7 3-8
Cumulative dose in BED10 (Gy)
Median 103.7 90.6
Range 92-118.5 72.7-107.6
SBRT, stereotactic body radiotherapy; PNS, paranasal sinus; NPC, nasopharyngeal
cancer; T, tumor; N, node; GTV, gross tumor volume; EBRT, external beam
radiotherapy; BED10, biologically equivalent dose in α/β ratio of 10.
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because the dose per fraction differed among patients.
The alpha/beta (α/β) ratio was assumed to be 10 for the
acute responding tissue and tumors and 3 for late-
responding tissues. The cumulative BED10 ranged from
72.7 to 118.5 (median 94.9) Gy. When converted to a
normalized total dose (NTD) of 1.8 Gy, the SBRT
NTD1.8Gy, α/β=10 ranged from 22.1 to 36.6 (median 30.3)
Gy, and the cumulative NTD1.8Gy ranged from 61.7 to
100.5 (median 79.9) Gy.
Combined chemotherapy was used in 19 (73.1%)
patients. Among these patients, 15 (57.7%) had received
concurrent chemotherapy, whereas the remaining 4
(15.4%) had received sequential chemotherapy. Debulk-
ing surgery was performed in 11 (42.3%) non-NPC
patients prior to EBRT.
Treatment compliance was excellent, and all patients
completed their planned treatments; however, in one NPC
patient, treatment was delayed for approximately 1 week
because of severe nausea during the SBRT procedure.
Based on combinatorial imaging studies or biopsy, 21
(80.8%) patients achieved CR, whereas 5 (19.2%) patientsTable 3 Nine cases of severe late complications
Patient
(age/sex)




31/M NPC, Lt. skull base 24.4 21/3
48/M NPC, Lt. skull base 8.5 21/3
48/M NPC, Rt. skull base 25.9 25/5
48/M NPC, Lt. skull base 4.4, 6.8 21/3
55/M SCC, Rt. BOT 15.8 16/2
82/M SCC, Lt. BOT 20.9 24/3
36/F ACC, Rt. lacrimal gland 30.0, 32.4, 30 25/5
41/F ACC, Lt. lacrimal gland 28.5, 28.5 20/5
59/M ACC, Rt. orbit 15.1 25/5
*Pontine necrosis was the definite cause of death
SBRT, stereotactic body radiotherapy; BED10, biologically equivalent dose in α/β rati
partial response; SCC, squamous cell carcinoma; BOT, base of tongue; F, female; ACachieved PR. As a result, the major response (CR+PR)
rate was 100%. The median time to the maximal re-
sponse was 2 (range 0.3− 7.4) months.
Patterns of failure and survival assessment
During the follow-up periods, a total of 8 (30.7%) recur-
rences initially developed at the following sites: 2 local fail-
ures, 1 regional failure and 5 DM. Two local failures were
infield recurrences, and 1 regional failure was an internal
jugular chain recurrence that was adjacent to the primary
target volume. The median time to the LRR and DM was
5.5 (range 4.6− 13.3) and 9.3 (range 1.0− 13.3) months, re-
spectively. Two infield recurrences from the two NPC
patients and 1 regional recurrence from a tonsillar carcin-
oma patient developed. Two bone metastases occurred
from NPC, 1 bone metastasis from lacrimal gland ACC, 1
skin metastasis from malignant melanoma, and 1 liver me-
tastasis from maxillary sinus adenocarcinoma.
The OS duration was assessed from the SBRT comple-
tion date to the date of death or the patient’s last visit. For
the entire study population, the median OS duration was
31.5 (range 4.5− 73.6) months. The 2- and 5-year actuarial
OS rates for the entire population were 61.5% and 46.2%,
respectively. The 1- and 2-year actuarial LRRFR for the
entire population were 91.4% and 86.3%, respectively.
Toxicity
A total of 13 patients experienced acute toxicities. Mild to
moderate (grade≤ 2) toxicities developed in six patients
who presented with mucositis, emesis, or conjunctivitis.
Severe (grade≥ 3) mucositis developed in seven patients,
including six grade 3 and one who was grade 4.
The frequency of late toxicities was unacceptably high.
Grade 1–2 manageable toxicities developed in nine
patients, including 1 minimal but prolonged mucosalResponse Cumulative
BED10 (Gy)
Late toxicity (RTOG late toxicity grade)
CR 101.5 Pontine necrosis (G5*)
PR 105.8 Lt. base of skull bone and
soft tissue necrosis (G4)
CR 107.6 Pontine necrosis (G3)
CR 118.5 Lt. nasopharyngeal wall soft tissue
necrosis (G4), temporal lobe necrosis (G3)
CR 94.6 Mucosal ulcer and necrosis (G4)
CR 96.3 Unhealing mucosal ulcer and bleeding (G4)
CR 90.6 Radiation retinopathy (G3), temporal
lobe necrosis (G3), NVG (G3)
CR 87.5 Radiation retinopathy (G3), NVG (G3)
CR 90.6 Optic neuropathy (G3)
o of 10; M, male; NPC, nasopharyngeal carcinoma; CR, complete response; PR,
C, adenoid cystic carcinoma; NVG, neovascular glaucoma.
Table 4 Risk factor analysis of developing grade ≥3 late
toxicities
Characteristics Grade≥3 late toxicities
No (n=17) Yes (n=9) p
Age 0.218*
<55 6 (35.3) 6 (66.7)
≥55 11 (64.7) 3 (33.3)
Gender 1.000*
Male 13 (76.5) 7 (77.8)
Female 4 (23.5) 2 (22.2)
Surgery 0.683*
No 9 (52.9) 6 (66.7)
Yes 8 (47.1) 3 (33.3)
Response 1.000*
CR 13 (76.5) 8 (88.9)
PR 4 (23.5) 1 (11.1)
Histology 0.692*
NPC 6 (35.3) 4 (44.4)
Non-NPC 11 (64.7) 5 (55.6)
EBRT dose (Gy) 0.525†
Median (range) 50.4 (39.6-60) 55.8 (45-70.2)
SBRT BED10 (Gy) 0.312
†
Median (range) 35.7 (13.2-38.4) 35.7 (28-43.2)
Total BED10 (Gy) 0.287
†
Median (range) 93.8 (72.7-107.6) 96.3 (87.5-118.5)
SBRT GTV (cc) 0.038†
Median (range) 21 (6.9-69.4) 47.7 (20.9-66.8)
SBRT fraction number 0.339†
Median (range) 5 (3-5) 3 (2-5)
SBRT fractional dose (Gy) 0.058†
Median (range) 5 (3-7) 7 (4-8)
*Fisher’s exact test; †Mann-Whitney U test
CR, complete response; PR, partial response; NPC, nasopharyngeal carcinoma;
EBRT, external beam radiotherapy; SBRT, stereotactic body radiotherapy; BED10,
biologically equivalent dose in α/β ratio of 10; GTV, gross tumor volume.
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oses or occlusions, 1 soft tissue and skin fibrosis, and 1
unhealed wound dehiscence.
Severe (grade≥3) late toxicities developed in nine (34.6%)
patients. The detailed characteristics of these nine patients
who experienced late toxicities are listed in Table 3. Four
cases developed within the target volumes, 5 cases devel-
oped in critical structures, and 1 was a combined case. The
median elapsed time of late toxicity after SBRT was 20.9
(range 4.4−32.4) months. More than 2 mixed late compli-
cations developed in three patients. In nine patients, eight
had achieved CR and one PR in their treatment courses,
and seven patients had been treated with concurrent che-
moradiation prior to their SBRT procedures. Bone or soft
tissue necrosis developed within a relatively a short period
of time (4.4−8.5 months) in comparison to the develop-
ment of other neuronal complications. We investigated
whether patient and treatment characteristics would be
associated with late complications. Among the variables, a
large GTV in SBRT was only significantly associated with
late toxicities (p=0.038), and SBRT fractional dose was also
a marginally significant factor (p=0.058) (Table 4).
There were 2 deaths due to SBRT-related late toxici-
ties. One patient suffered from prolonged poor oral in-
take due to a non-healing mucosal ulcer, and he finally
died from a poor general condition and asphyxia caused
by massive oral bleeding. Another patient died from
neurologic deteriorations arising from pontine necrosis
from which he experienced a number of neurological
symptoms, including hoarseness, shoulder pain, limb
weakness and aspiration, and finally expired 38.2 months
after the SBRT procedure. Figures 1, 2, 3 and 4 show
representative cases of late complications.
Dosimetric analysis of late complications
The results of detailed dose-volume analyses of 4 major
late complications are described in Table 5. The median
EBRT and SBRT prescribed doses were 50.4 (range 45–
70.2) and 25 (range 20–25) Gy, respectively. We esti-
mated the D30% (a dose covering 30% of the organ vol-
ume) and D50% in the EBRT course and D10%, D30%,
D50%, V50% (an organ volume that received 50% of the
total dose) and V70% in the SBRT course to evaluate par-
tial volume dosimetry. The Dmax (maximum dose) for
the organ at risk (OAR) was higher than the prescribed
dose in 6 out of 7 cases. The SBRT V50% was higher than
20− 30% in all of the pontine necrosis, optic retinopathy
and optic neuropathy cases.
Discussion
The present study showed that modern SBRT boost
technique was highly efficacious dose escalation modal-
ity in terms of local control. However, we also observed
high late complications.In the current study, the major response rate with early
local control was 100%, including 21 (80.8%) CR. Despite
the treated tumors having heterogeneous compositions
and treatment characteristics, the frequency of infield
local recurrence was low (7.7%) after long-term follow-up.
The importance of improving local control is demon-
strated in the present study as well as in previous reports,
which indicates that local recurrence exacerbates and
deteriorates the OS [5]. Due to the fact that the DM
(19.2%) was the major pattern of failure, the results sup-
port the need for more effective systemic chemotherapy
or targeted therapy in patients who are treated with highly
ablative tools for local treatment.
Figure 1 Radiation retinopathy, neovascular glaucoma and temporal lobe necrosis after SBRT. This patient was a 36-year-old female with
adenoid cystic carcinoma (ACC) of the right lacrimal gland with intraorbital invasion (a). She underwent right orbitotomy and neck dissection
followed by EBRT at 45 Gy and SBRT at 25 Gy in 5 fractions (b) and achieved CR in the response evaluation (c). Two years after SBRT, a cataract
operation (Phaco+ PCL) of the right eye was performed. She experienced progressive vision loss in the right eye and was diagnosed with
radiation retinopathy and neovascular glaucoma in an ophthalmologic exam 30 months after SBRT. Follow-up serial perfusion CT and functional
MRI of the brain indicated right temporal lobe necrosis of the brain (d).
Figure 2 Pontine necrosis after SBRT. This patient was a 48-year-old male with type I NPC (a). He was treated with cisplatin-based concurrent
chemoradiation via EBRT up to 59.4 Gy followed by CK-RS at 25 Gy in 5 fractions (b) and achieved CR in the response evaluation (c). Pontine
necrosis developed 25.9 months after SBRT (d). He experienced various neurologic symptoms, including dizziness, gait disturbance, hoarseness,
limb weakness, dysarthria and other cranial nerve signs and was still under rehabilitation and supportive care for debilitating symptoms at the
time of analysis.
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Figure 3 Non-healing mucosal ulcer and bleeding after SBRT. This patient was an 82-year-old male with cancer of the base of the tongue. He was
diagnosed with left posterolateral SCC of the base of the tongue (T2N0M0) (a) and was treated with EBRT at 45 Gy followed by CK-RS boost at 24 Gy in
3 fractions (b). He achieved CR in the response evaluation (c); however, he suffered from prolonged chronic mucositis and poor oral intake and finally
died from asphyxia that was caused by a massive ulcer bleeding 22.6 months after SBRT, despite medical treatment (d).
Figure 4 Left nasopharyngeal wall soft tissue necrosis and temporal lobe necrosis after SBRT. This patient was a 48-year-old male with type I NPC
(T4N2M0) (a). He was treated with cisplatin-based concurrent chemoradiation via EBRT up to 70.2 Gy followed by SBRT at 21 Gy in 3 fractions due to persistent
disease in the left skull base (b). Although he achieved CR and no loco-regional or distant metastasis occurred, left nasopharyngeal wall soft tissue necrosis (c)
and temporal lobe necrosis (d) developed 4.4 and 7.2 months after SBRT, respectively. Temporal lobe necrosis and abscess formation, which might have arisen
from adjacent nasopharyngeal soft tissue necrosis, were confirmed by surgical specimen pathology. He finally died 9.3 months after the SBRT treatment.
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(cc) (Gy) (Gy/Fx) (Gy) (Gy) (Gy) (Gy) (Gy) (Gy) (%) (%)
Pontine necrosis (Brainstem)
1 24.67 59.4 25/5 43.5 40.9 24.6 19 15.4 12.8 23.5 0.7
2 23.55 55.8 21/3 36.2 19.7 27.3 24.2 20.1 16.0 54.3 24.9
Temporal lobe necrosis (Temporal lobe)
1 63 45 25/5 48.1 45.3 28.4 17.9 10.3 6.2 11.2 4.4
2 66.02 70.2 21/3 37.4 11.7 25.0 16.5 8.9 4.9 18.8 5.7
Optic retinopathy (Eyeball)
1 10.7 45 25/5 45.1 45.1 27.7 23.7 18.4 13.3 35.9 12.8
2 11.2 50.4 20/5 52.1 49 22.5 21.1 18 13.5 50.6 25.9
Optic neuropathy (Optic nerve)
1 0.483 45 25/5 41.3 40.7 27.8 27.3 27.0 26.7 100 97.2
OAR, organ at risk; EBRT, external beam radiotherapy; SBRT, stereotactic body radiotherapy; Fx, fraction; Dx%, dose covering x% of total volume; Dmax, maximum
dose; Vx%, volume receiving x% of prescribed dose.
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strates somewhat unfavorable results. Acute complications
(27%) as well as severe late complications (34.6%) were
observed to unexpectedly develop at high frequencies. Al-
though the Quantitative Analysis of Normal Tissue Effects
(QUANTEC) [13], which is a new dose-volume parameter
in late complications, have been recently reported, they have
demonstrated a disagreement among existing models and
lack significant published data, particularly in the context of
hypofractionated RT. Accordingly, there is a lack of firmly
established dose-volume criteria regarding late toxicities for
hypofractionated SBRT at present. In our study, seven
(77.8%) out of nine patients who developed severe late com-
plications had received prior concurrent chemoradiation,
and SBRT was continuously employed after only 2 weeks.
Therefore, aggressive treatment within a short period might
lead to these unacceptable toxicities. There were 2 types of
late toxicities in our data: toxicity within target volumes and
toxicity in neighboring normal structures. Because one case
of early death were caused by sustained chronic bleeding-
related aspiration, prolonged mucositis or unhealed ulcers,
late toxicities arising from target volumes or swallowing
structures should not be overlooked. Consequential late
effects might be another related factor, as some patients
experienced severe early toxicity. Late complications in crit-
ical organs developed within relatively consistent time inter-
vals after SBRT. Pontine necrosis, radiation retinopathy and
NVG progressed in around 2–3 years after SBRT.
Debus et al. [14] reported that the mean time to onset of
brainstem symptoms was 17 (range, 4.5− 92) months in
patients who developed brainstem toxicity after photon
and proton radiotherapy for chondrosarcoma and skull
base tumors. Symptoms appeared within 3 years in 89.5%
of patients, and there was a trend of a higher grade oftoxicity in patients who had late symptom onsets. In most
earlier series by Jiang et al. [15], the actuarial incidence of
symptomatic retinopathy and neuropathy constantly
increased even after 5 years in patients who had been trea-
ted with doses higher than 60 Gy. The incidence of TLN
was particularly high in a series by Hara et al. [10] in
which the authors prospectively performed SBRT boosting
in a single fraction after EBRT for patients with locally
advanced NPC. Although the overall local control was ex-
cellent (98% at 5 years), 12% of patients developed TLN
from 18 to 97 months after completion of SBRT boost. As
shown in previous data, toxicity results in the scope of
hypofractionation RT were scarce and insufficient to
propose a standardized guideline.
Given the high α/β ratio in the majority of head and
neck tumors and the low α/β ratio in the surrounding
normal organs, hypofractionation with extremely high
fraction sizes might not be a relevant dose scheme.
Moreover, a dose calculation method using a simple
dose summation of BED based on the LQ-model is a
controversial matter [16,17] and has some limitations
because, hypothetically, the normal tissue response to a
high dose per fraction is potentiated by direct cytotoxic
damage and vascular/stromal damage [16].
From our data, we can conclude that the existence of
high-grade early toxicity, aggressive treatment without suffi-
cient break time, a large treatment volume and high frac-
tional dose are consistently associated with late
complications. The majority of early deaths without evi-
dence of recurrent disease were observed to be related to
persistent swallowing problems, chronic mucositis, or the
impairment of neuronal functions (e.g., gag reflex). In
addition, there were several cases of late complications that
derived from eye and neuronal structures. Although rapid
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were several cases with high V50% in our study. Therefore,
we need to more strictly reduce high-dose volumes in these
organs to avoid severe late complications.
The main advantage of the current study is the achiev-
ability of long-term follow-up in the entire patient cohort.
The results from the current series were concordant with
the early experience of hypofractionated RT in the histor-
ical data with regard to the possibility of late unfavorable
sequelae [18]. We have changed our treatment planning
to decrease the fractional dose and are currently applying
the SBRT boost technique only in selective cases with lim-
ited volumes in the head and neck area because a large
treatment volume and a high fractional dose were the sig-
nificant related parameters that were predictive of the risk
of developing late toxicities in our study.
In conclusion, the present study shows that the mod-
ern SBRT boost technique is a highly effective treatment
tool for local tumor control in extracranial head and
neck cancers. However, we observed serious late compli-
cations related with high boost volume and large frac-
tional dose. Although generally considered to be a safe
modality, hypofractionated SBRT boost should be
employed with caution in selected patients due to its po-
tentially hazardous effects in head and neck regions.
Further validations for determining the appropriate bio-
logical model in the field of hypofractionation RT are
warranted from future clinical studies.
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